Open AccessSurgical treatment of HCC in a patient with lamivudine-resistant hepatitis B cirrhosis with adefovir dipivoxil
Author(s) -
Takashi Akima,
Masaya Tamano,
Hidetsugu Yamagishi,
Keiichi Kubota,
Takahiro Fujimori,
Hideyuki Hiraishi
Publication year - 2010
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v2.i8.318
Subject(s) - adefovir , lamivudine , medicine , hepatocellular carcinoma , cirrhosis , liver function , gastroenterology , hepatitis b virus , hepatitis b , virology , virus
We describe a 77-year-old woman with chronic hepatitis B who became resistant to lamivudine. She was started on adefovir (10 mg daily) while still continuing lamivudine therapy. Four mo later her liver function improved and serum Hepatitis B virus (HBV)-DNA level became undetectable. Three years after the start of additional adefovir treatment, hepatocellular carcinoma (HCC) was detected and the patient underwent a successful hepatectomy. Our findings suggest that the addition of adefovir to ongoing lamivudine therapy cannot completely suppress hepatocarcinogenesis, but is useful for improving liver function in patients with lamivudine-resistant HBV-related cirrhosis, allowing HCC surgery.